Effect of left ventricular hypertrophy on long-term survival of patients with coronary artery disease following percutaneous coronary intervention
Abstract
Overview
The impact of left ventricular hypertrophy
(LVH) on survival among patients with established
coronary artery disease (CAD) is not
well understood. We sought to evaluate the
effect of LVH on the survival of patients with
CAD following percutaneous coronary intervention
(PCI). Three hospitals in New York
City contributed prospectively defined data on
4284 consecutive patients undergoing PCI. Allcause
mortality at a mean follow-up of three
years was the primary endpoint. LVH was present
in 383 patients (8.9%). LVH patients had a
greater prevalence of hypertension (88% vs.
68%, p<0.001), vascular disease (21% vs. 6.6%, p=0.001), and prior heart failure (10% vs. 5.5%, p<0.001). LVH patients presented less often with one-vessel disease (38% vs. 50%, p=0.040) and more often with two- (34% vs. 29%, p=0.014) or three-vessel (22% vs. 18%, p=0.044) disease. Ejection fractions and angiographic success were similar in both groups. In-hospital mortality did not differ between groups. At three-year follow-up, the survival rate for patients with LVH was 86% vs. 91% in patients without LVH (log-rank p=0.001). However, after adjustment for differences in baseline characteristics using Cox proportional hazards analysis, LVH was found not to be an independent predictor of mortality (hazard ratio, 0.93; 95% confidence interval, 0.68-1.28; p=0.67). We conclude that LVH at the time of PCI is not independently associated with an increase in the hazard of death at three years.
Keywords
Angioplasty, stent, left ventricular hypertrophy, survival.
Article Information
Correspondence
David L. Brown, Division of Cardiovascular Medicine, Stony Brook University Health Sciences Center T 16-080, Stony Brook, NY 11794-8171, USA. E-mail: david.brown@stonybrook. edu
Received
2009-10-17T00:00:00
Further Resources
Trending Topic
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk than the general population. A recent study demonstrated a 2.1% higher stroke rate in the […]
After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...
Cardiovascular medicine continues to advance at a remarkable pace, driven by innovation, interdisciplinary collaboration and an ever-deepening understanding of disease mechanisms. As patient populations age and chronic conditions become increasingly complex, the field stands at the intersection of precision therapy, ...
Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing and is an integral part of the European Heart Rhythm Association (EHRA) core curriculum for the device specialist.1–6 Left bundle branch ...
Welcome to this issue of Heart International. As ever, we aim to provide our readers with the latest developments, insights, and evidence-based discussions in cardiovascular care. This edition is particularly poignant, as we begin with a heartfelt tribute to an ...
Forty-seven years ago, Andreas Gruentzig introduced ‘percutaneous transluminal coronary angioplasty’ (PTCA) as a new approach to treating symptomatic occlusive coronary artery disease.1 The mechanism of balloon angioplasty (BA) formed the foundation around which newer equipment and technologies were developed, including ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1Â Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2Â It is conventionally performed via the trans-femoral (TF) route. Recently, however, ...
We are sorry to announce the death of one of our valued editorial board members, Dr Richard Heuser (November 17, 1950–May 23, 2024). Richard R Heuser, MD, FACC, FACP, FESC, MSCAI, was an internationally recognized cardiologist, inventor, educator and author, and was a ...
Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment ...
Clinically relevant tricuspid regurgitation (TR) is a common disorder, affecting approximately 4% of people 75 years of age or older.1Â If left untreated, severe TR results in volume overload and right ventricular remodelling. This eventually leads to symptomatic right-sided heart failure, along ...
In this issue of Heart International, we are delighted to present a collection of insightful articles that encompass a wide spectrum of topics within the field of cardiovascular medicine. As we navigate the landscape of cardiovascular disease, heart failure, preventative ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
